Clinical trials: Neoplasms Recurrence
Lung Cancer
Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004186
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Alabama at Birmingham
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
This phase I trial studies the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma that has come back (relapsed) or does not respond…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
- Trial name
- NCT01722305
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Endometrial Cancer
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per…
- Trial name
- XPORT-EC-042 (NCT05611931)
- Testing
- Selinexor
- Where
- 185 sites in United States, Australia and 15 more
- Volunteers
- 257 people
- Sponsor
- Karyopharm Therapeutics Inc
HNSCC
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with…
- Trial name
- NCT07136545
- Testing
- HCB101, Pembrolizumab
- Where
- 3 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01215123
- Testing
- Bevacizumab
- Where
- 12 sites in Argentina
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT06970496
- Testing
- B019
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Head and Neck Neoplasms
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
This proof-of-concept study aims to assess the clinical and biological effects of Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma of the head and neck (HNSCC).
- Trial name
- ATHENA (NCT03818061)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in France
- Volunteers
- 33 people
- Sponsor
- Centre Leon Berard
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population, with 5-year survival rates ranging from 10% to 30%.
- Trial name
- NCT02977169
- Testing
- PORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Squamous Cell Carcinoma, Cancer
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced
- Trial name
- NCT03383094
- Testing
- Pembrolizumab, Radiation therapy, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 126 people
- Sponsor
- Loren Mell, MD
Leukemia
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer the in laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01229956
- Testing
- DNA methylation analysis, gene expression analysis, microarray analysis
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00002922
- Testing
- paclitaxel
- Where
- 24 sites in United States, South Africa
- Sponsor
- Eastern Cooperative Oncology Group
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00031629
- Testing
- Docetaxel, Filgrastim, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, HER2-negative Breast Cancer
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
This phase II is studying the side effects and how well carboplatin and paclitaxel albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab before surgery works in treating patients with stage…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00618657
- Testing
- Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of California, Irvine
Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor microenvironment.
- Conditions
- Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head, Metastatic Squamous Cell Carcinoma Neck
- Trial name
- NCT03198130
- Testing
- REGN2810
- Where
- 6 sites in South Korea, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01746836
- Testing
- Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Unrecognized Condition
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
Doxorubicin is an anthracycline antibiotic that is part of the standard treatment for many pediatric malignancies, but its long-term cardiotoxicity cannot be ignored.
- Trial name
- NCT04213612
- Testing
- pegylated liposomal doxorubicin, cyclophosphamide, vincristine,
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.